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Abstract— Increasing the odds of hit identification in screening 
is of significance for drug discovery. The odds for finding a hit 
are closely related either to the diversity of libraries or to the 
availability of focused libraries. There are no truly diverse 
libraries and it is difficult to design focused libraries without 
sufficient information. Hence it is helpful to consider alternative 
approaches that can enhance the odds using existing libraries. 
Multiple members of a protein family have been considered 
collectively in inhibitor design, on the basis of the correlation 
between protein families and ligands derived from specific 
compound classes.  Such a correlation has been exploited in 
various drug discovery studies and a general receptor-homolog-
based screening scheme may be devised. The feasibility of such a 
scheme in enhancing the odds of hit identification is discussed. 
 
Index Terms—Homolgy, inhibitors, screening. 
 
I. INTRODUCTION 
High-throughput screening and virtual screening has 
been extensively used in drug discovery [1, 2]. The odds 
for finding a hit depends on the diversity of compound 
libraries used [3]. There is no truly universal set of 
representative compounds and the screening has practically 
been conducted against subsets of molecules [4, 5x], which 
may result in useful hits being missed. This problem was 
illustrated recently by Oldenburg [3] in an example of two 
highly similar compounds of the steroid family, testosterone 
and estrogen, which differ only by a methyl group and a few 
double bonds.  If only the first is included in a library for 
screening against estrogen receptor, estrogen would not be 
discovered. The same is true if one starts with estrogen and 
tests it against testosterone receptor.  
   Such a problem is likely of particular concern to 
screening for agonist/activator drugs that generally require 
more specific structural binding configuration than that of 
antagonist/inhibitor drugs. A search of Medline shows that 
less than 12% of the publications in drug screening are related 
to agonist/activator drugs, which may be partly due to the 
difficulty in finding an agonist or activator hit. 
Agonist/activator drugs constitute an important drug class. A 
search of the therapeutic target database [5] finds 44 targets of 
agonist/activator drugs, many of which are important 
receptors. Hence, methods for improving the odds of 
screening of agonist/activator drugs as well as 
 
 
antagonist/inhibitor drugs are potentially useful in new drug 
discovery. 
 Increasing the size of libraries in a random fashion may not 
always be effective or practical for solving this problem [4]. 
Drug-like compounds have been found sparsely distributed 
through chemistry space [6]. As a result, the design of focused 
libraries can be a difficult task without sufficient information. 
Therefore it is helpful to consider alternative approaches that 
can potentially enhance the odds of hit identification without 
relying solely on the simple expansion of existing libraries. 
Recent developments in exploiting the correlation between 
protein families and ligands from specific compound classes 
point to a receptor-homolog-based screening scheme for 
improving the odds of hit identification. 
 
II. EXPLOITATION OF THE CORRELATION BETWEEN 
PROTEIN FAMILIES AND LIGANDS DERIVED FROM  
SPECIFIC COMPUND CLASSES 
 
 In the search of inhibitors of specific cyclin-dependent 
kinases, multiple members of the kinase family were 
considered in a collective manner on the basis of their 
common feature of ligand-binding mode [7]. Based on the 
known binding mode of purine olomoucine at the ATP-
binding site, compounds were designed from combinatorial 
libraries of 2,6,9-trisubstituted purines. Selective inhibitors for 
subsets of cyclin-dependent kinases were developed from 
these libraries.  
  The correlation between members of kinase family and 
inhibitors derived from specific compound classes has been 
shown and exploited in various studies [8]. For instance, 
compounds based on quinazoline scaffold were found to 
exhibit good structure-activity relationship against EGFR 
tyrosine kinase and other related kinases (30-34). Potent ATP-
binding site inhibitors were derived from this scaffold for 
EGFR tyrosine kinase (31 or 32), c-erbB2/c-erbB4/EGFR (42, 
45, 62), RAF kinase (61), CSF-1R (47, 51), and VEGFR (63-
72), some of which are undergoing clinical trials. Inhibitors 
were derived from the phenylamino-pyrimidine class for 
PDGFR (80?), PKC-a (75) and EGFR tyrosine kinase (82). A 
number of indolocarbazole derivatives were found to be 
inhibitors of NGF receptor (210), protein kinase C (215), and 
PDGR (213).  Pyrazolo[d]pyrimidine derivatives were 
designed as inhibitors of LcK (120), v-Src (220), CSF-1R 
(47), and EGFR (47).  
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 This correlation also appears in other protein families and 
applies to agonists/activators. A few examples are serine 
protease and peptide-like inhibitors (x1), nuclear hormone 
receptors and steroid agonists (x2), and members of G-protein 
coupled receptors and catecholamine agonists (x2).  
There have been suggestions of exploiting this relationship 
to various drug discovery problems [10]. It was proposed that, 
by screening a common and diverse set of small molecule 
inhibitors against a set of proteins from a family, specific 
structure-activity relationship homology can be derived from 
which potential drug discovery targets can be grouped (z1).  
Based on the common molecular theme for ligands with a 
certain classes of drug targets it was suggested that, in stead of 
putting barriers of high-risk targets through expensive screens 
of large compound collections, focused libraries of specific 
compound classes should be tested first [9]. In order to direct 
discovery processes to tractable chemical libraries, potential 
targets can be screened from all members of a gene family that 
have proven records in drug development and chemistry effort 
can then be focused on the most intriguing targets (z2).  
 
A. Screening against of receptor-homologs as a general 
scheme? 
It is of interest to explore the possibility of further 
extending the protein-family-based approach into a more 
general receptor-homolog-based scheme for drug screening. 
In this scheme, as illustrated in Figure 1, screening is 
conducted against a receptor and its homologs which are 
defined as proteins of similar sequence in the ligand-binding 
domain. These homologs likely share common structural 
features at ligand-binding sites and structurally similar ligands 
may exist for some of these homologs. If one or more of these 
ligands is identified as a hit for the entire homolog group, the 
rest may be generated by focused library design based on the 
identified hits. The subsequent screening of these focused 
libraries against the receptor may lead to the identification of 
the specific ligands for that receptor. 
    In the testosterone-estrogen example, if the same set of 
compounds is used for screening against estrogen receptor and 
all of its sequence homologs (including testosterone receptor), 
testosterone would be identified as a hit for the entire receptor 
group.  A focused library of steroid analogs may be 
constructed based on the framework of testosterone, which 
likely include estrogen. A subsequent screening of this 
focused library against estrogen receptor would discover 
estrogen. The odds of finding an agonist hit are thus 
significantly increased. 
   The feasibility of this scheme depends on the existence of 
structurally similar ligands, particularly agonists/activators, 
for at least some of the homologs. Structurally similar agonists 
are searched for two receptors, estrogen receptor and 
adrenoceptor, and their sequence homologs. The identified 
homologs of these receptors along with structurally similar 
agonists are given in Table 1 and 2 respectively.  Certain 
homologs are excluded from these two groups which include 
orphan receptors with unknown ligand and peptide-agonist 
receptors or lipid-agonist receptors with binding sites covering 
sections different from that of the respective common binding 
sites defined by the estrogen receptor or adrenoceptor [11,12]. 
Structurally similar agonists are found for 7 out of 8 homologs 
of estrogen receptor [13-15] and for 4 out of 8 homologs of 
adrenoceptor [16-19] respectively. Moreover, agonist 
superficially similar to the other agonists is found for a 
homolog of estrogen receptor and that of adrenoceptor 
respectively. Thus it appears that compounds of common 
structural framework can be found for a substantial portion of 




The correlation between protein families and ligands of 
common structural theme has been exploited in various drug 
discovery studies.  A general receptor-homolog-based 
screening scheme may be devised based on this correlation. 
From the study of specific cases, it appears to be feasible to 
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